PD-1 and PD-L1 inhibitors- Rising with existing marketed and drugs

Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) is the most talked about immuno-oncology target. Programmed Death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, particularly cytotoxic T cells. Therapeutics that blocks this interaction has demonstrated promising clinical activity in several tumor types. PD-L1 not only provides the immune escape for tumor cells but also stimulate apoptosis switch on activated T cells.

According to DelveInsight’s report “PD-1 and PD-L1 Inhibitors Competitive Landscape, Pipeline and Market Analysis, 2017”, currently there are about five marketed drugs in this arena and more than 50 products are in the pipeline in various development stages. Products that are in the phase III of development and about to enter the market are – PDR001 (Novartis), REGN2810 (Regeneron), SHR1210 (Incyte). Drugs that are used for this therapy have different molecular types like proteins, fusion proteins, antibody, monoclonal antibody, small molecule, siRNA etc, depending on their derived sources. Also, the route of administration can be subcutaneous, intravenous or oral.

As per the details provided in the report by DelveInsight, companies are working on different technologies for developing drugs in the respective domain, example of such technologies are 3D antigen design technology (Tikcro Technologies), Affimer Technology (Avacta Life Sciences), Avidocin Technology (Merus), Bispecific Fc Domains Technology (Xencor) etc. Currently, maximum products are in pre clinical phase showing the increased interest of companies in the given arena.

DelveInsight’s latest report has covered the complete PD-1 and PD-L1 Inhibitors domain. Complete insight about all the marketed drugs and pipeline products along with the different technologies being used by the companies in the PD-1 and PD-L1 arena is provided. Information about the future products that are about to enter the market and can change the present market scenario, drug profiling of the current marketed products and dormant product information is also covered.

Also, the complete coverage of ASCO 2017 including the latest addition in the market, existing drug achievements and clinical trial results of different drugs is a fringe benefit for the companies and institutes working for the advancement of the respective technology.

Reasons to buy:

• The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors.
• The report provides information about the pipeline products and drug profiling of the marketed drugs, MOA, dormant products.
• The report covers the latest technologies that are being used by different companies.
• Pipeline product coverage based on various stages of development ranging from discovery stage till late stage products.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.

DelveInsight
New Delhi, India

This release was published on openPR.